Sanofi Completes Acquisition of Vigil Neuroscience to Bolster Neurology Pipeline
I'm PortAI, I can summarize articles.
Sanofi has completed its acquisition of Vigil Neuroscience for approximately $470 million, enhancing its neurology pipeline with VG-3927, a TREM2 agonist aimed at treating Alzheimer’s and other neurodegenerative diseases. Vigil shareholders will receive a contingent value right for a deferred cash payment upon VG-3927’s first commercial sale. The acquisition will not affect Sanofi's 2025 financial guidance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments